Study Overview:
We are currently enrolling patients for a research study comparing the effectiveness of the Vivaer: a non-invasive, in-office procedure that uses radiofrequency energy to remodel nasal tissues and improve airflow nasal airway obstruction (NAO) compared to patients that undergo a more involved surgical procedure to treat the same level of nasal obstruction.
How It Works:
- Performed under local anesthesia in a physician’s office.
- A small stylus is inserted into the nasal passages.
- The stylus emits radiofrequency energy to heat and shrink nasal tissues.
- Reshapes the nasal valve area, the narrowest part of the nasal passages, to enhance airflow.
- The procedure takes 15-30 minutes with minimal discomfort.
Benefits:
- Non-invasive alternative to surgery.
- Provides long-lasting relief from nasal congestion.
- Enhances breathing during exercise, sleep, and daily activities.
- Quick recovery – patients typically resume normal activities immediately.
Who Can Participate?
We are seeking individuals experiencing nasal airway obstruction due to:
- Enlarged nasal turbinates
- Nasal valve collapse
Exclusion Criteria:
- Severe nasal deformities or previous nasal obstruction surgery.
- Individuals for whom the procedure may not be effective.
Study Background:
Clinical studies have shown significant improvements in nasal breathing and quality of life following Vivaer treatment:
- 96% of patients experienced significant improvement in nasal breathing.
- 93% of patients reported better airflow during exercise.
- 96% of patients reported improved sleep quality.
While Vivaer is considered safe, potential temporary side effects include mild swelling, congestion, and crusting.
Under this study, the procedure will be billed to the patient and/or their insurance, but there is a monetary incentive to help offset the costs.
Interested in Participating?
👉 To learn more or see if you qualify, contact us at 210 545-0404 or visit www.alamoent.com and request an appointment. You can also email direct to the research department: Maxine Mata (m.mata@alamoent.com) or Robert Gonzalez (r.gonzalez@alamoent.com)